135 results about "Enoxolone" patented technology

A method for improving health conditions of mammals or livestock by feeding, to the mammals or livestock, a licorice extract including: (A) glycyrrhizic acid, a glycyrrhizic acid derivative, glycyrrhetinic acid, and / or a glycyrrhetinic acid derivative; (B) licorice saponins other than (A); and (C) licorice flavonoids; (B) including at least a licorice saponin H2, a licorice saponin G2, and macedonoside A, (C) including at least liquiritin apioside, isoliquiritin apioside, and isoliquiritin, where feeding is of 0.017 g / day / head or more of the licorice saponin H2, 0.002 g / day / head or more of the licorice saponin G2, and 0.002 g / day / head or more of the macedonoside A, 0.001 g / day / head or more of the liquiritin apioside, 0.001 g / day / head or more of the isoliquiritin apioside, and 0.001 g / day / head or more of the isoliquiritin.

The invention relates to a glabridin self-assembly inclusion with an ultra-small particle size as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The composition disclosed by the invention is prepared from the following components in parts by weight: 0.5 to 5 parts of glabridin, 10 to 30 parts of polyhydric alcohol, 0.4 to 6.5 parts of liquorice root carrier component, 1.5 to 3 parts of nonionic emulsifier A, 0.45 to 1.8 parts of nonionic emulsifier B and 53.7 to 87.15 parts of water, the liquorice carrier component comprises at least one of glycyrrhizic acid, ammonium glycyrrhizinate and glycyrrhetinic acid; the nonionic emulsifier A is a nonionic emulsifier of which the hydrophilic-lipophilic balance value HLB is greater than 9; and the nonionic emulsifier B is a nonionic emulsifier with a hydrophilic-lipophilic balance value HLB of 2-4. The glabridin self-assembly inclusion disclosed by the invention is smaller in particle size, good in wrapping performance and good in targeting property; the stability is good, glabridin wrapping does not separate out, and the transdermal absorption rate is higher.

The invention provides glycyrrhizic acid / glycyrrhetinic acid-triethanolamine composite hydrogel as well as a preparation method and application thereof, and belongs to the technical field of preparation of biological medicine carriers and composite materials. According to the invention, glycyrrhizic acid or glycyrrhetinic acid is taken as a raw material, triethanolamine is taken as a cross-linking regulating agent, and the composite hydrogel with stable mechanical properties, high drug loading efficiency and anti-inflammatory synergistic activity is prepared through a mild physical and chemical cross-linking reaction; the preparation process of the composite hydrogel does not need a toxic cross-linking agent, the reaction condition is mild, the raw materials are cheap and easy to obtain, and large-scale production can be realized; the composite hydrogel presents a multi-group ionic bond cross-linked structure, can be used as a carrier of a pH responsive drug, and has good practicability.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the field of biological medicine, particularly discloses application of glycyrrhetinic acid or glycyrrhetinic acid lipidosome in preparation of an abdominal aortic aneurysm protection medicine, and reveals that glycyrrhetinic acid can effectively improve death of mice after aorta rupture caused by Ang II treatment, can obviously improve degradation of an aorta elastic fiber layer caused by Ang II treatment, and can improve the aortic aneurysm protection effect. The macrophages induced by lipopolysaccharide (LPS) can be promoted to be polarized to M2 type; the glycyrrhetinic acid is used for intervention before Ang II treatment, the occurrence of Ang II induced abdominal aortic aneurysm can be relieved, the survival rate of mice is increased, and it is indicated that the glycyrrhetinic acid can be used for preparing the medicine for relieving the abdominal aortic aneurysm. Furthermore, the glycyrrhetinic acid is entrapped into the liposome, so that the solubility and bioavailability of the glycyrrhetinic acid are improved, meanwhile, after glycyrrhetinic acid coating is carried out by utilizing a nanotechnology, the dosage of the glycyrrhetinic acid can be effectively controlled, and the curative effect of the glycyrrhetinic acid is further improved and enhanced.

To provide a bactericidal agent for penetration into the deep layer of dental plaque that allows a bactericidal component to penetrate from the surface layer to the inner deep layer of dental plaque.SOLUTION: Provided is a bactericidal agent for penetration into the deep layer of dental plaque that comprises glycyrrhetinic acid (X) and a cationic bactericidal agent (Y) as active ingredients.SELECTED DRAWING: None

The invention discloses application of glycyrrhetinic acid in reducing reproductive toxicity of zearalenone to replacement gilts, and belongs to the technical field of animal breeding. Zearalenone can promote advanced development of internal and external reproductive organs such as uterus, ovary, vagina and the like, cause pathological changes of the reproductive organs, disturb the estrus cycle and the like to exert reproductive toxicity on the replacement gilts, so that the reproductive potential of the replacement gilts is influenced. By adding glycyrrhetinic acid into the replacement gilt feed, the development of the uterus, ovary and follicle of the replacement gilt can be promoted, the harm of ZEA to the ovary and uterus of the replacement gilt is reduced, and the estrus initiation of the replacement gilt is improved, so that the breeding potential of the gilt is improved, and the annual productivity of the replacement gilt is improved.

The invention belongs to the technical field of antiviral drugs, and particularly relates to application of 18 beta glycyrrhetinic acid in preparation of drugs for resisting porcine pseudorabies virus infection. The invention provides application of 18 beta glycyrrhetinic acid in preparation of a medicine for resisting porcine pseudorabies virus infection in order to solve the problem that an existing PRV (porcine reproductive virus) new prevalent strain II type lacks vaccines and medicines capable of effectively protecting the existing PRV new prevalent strain II type. Meanwhile, the invention also provides a medicament containing 18 beta glycyrrhetinic acid for resisting porcine pseudorabies virus infection. It is found for the first time that the 18 beta glycyrrhetinic acid can inhibit adsorption and replication of PRV on PK-15 cells, and the 18 beta glycyrrhetinic acid has a very remarkable effect on resisting PRV, so that the 18 beta glycyrrhetinic acid can be used for preparing the medicine for resisting porcine pseudorabies virus infection, is safe, non-toxic and harmless, and provides an effective and reliable natural medicine for prevention, control and adjuvant treatment of porcine pseudorabies virus infection.

The invention provides a double-fermentation thick skin factor liposome, a preparation method thereof and a cosmetic, and relates to the technical field of biomedical materials. The double-fermentation thick skin factor liposome comprises alkaloid, a double-fermentation thick skin factor, phospholipid and short-chain fatty alcohol, the dual-fermentation skinning factor comprises galactose yeast fermentation liquor, lactic acid bacteria NP and glycyrrhetinic acid. According to the double-fermentation thick-skin factor liposome provided by the invention, the double-fermentation thick-skin factor has excellent anti-aging and anti-aging effects, can remarkably improve the cell activity and enhance the skin barrier, and is prepared into a liposome form, and glycyrrhetinic acid in the double-fermentation thick-skin factor and sophocarpidine are utilized to form a supramolecular eutectic. The double-fermentation thick skin factor liposome has double advantages of the supramolecular eutectic solvent and the liposome, the double-fermentation thick skin factor is efficiently promoted to enter the skin, the skin residence rate is increased, and the local treatment effect is effectively improved to play the anti-aging effect of the double-fermentation thick skin factor liposome.

The application discloses application of glycyrrhetinic acid as a feed additive to improve the egg laying rate of laying hens. In the laying hen diet of the application, only glycyrrhetinic acid is added, and no chemical synthetic drugs and hormone substances are added, so that the safety of chicken and egg products is guaranteed from the source. The application fully considers the feed cost in application and feed preparation problems, selects glycyrrhetinic acid with low cost, fully plays the medicinal value of traditional Chinese medicinal materials, and the glycyrrhetinic acid is a natural plant extract, has no toxic side effects on laying hens, meanwhile, the preparation and purification method of the glycyrrhetinic acid is simple, the market price is low, and the glycyrrhetinic acid has the advantages of large-scale application.

The present invention aims to provide a scalp composition, such as a hair growth agent or hair restoration agent, comprising at least glycyrrhetinic acid or a salt thereof, polyoxyethylene hydrogenated castor oil, and ethanol, wherein the composition does not cause the precipitation of precipitates over time. [Solution] A scalp composition that does not produce precipitates and / or insoluble matter can be provided by comprising (A) glycyrrhetinic acid or a salt thereof, (B) polyoxyethylene hydrogenated castor oil, (C) ethanol, and (D) one or more selected from the group consisting of 1,3-butylene glycol and polyethylene glycol monooleate.

The invention is suitable for the technical field of medicine health, and particularly relates to a glycyrrhetinic acid lutein ester compound, a preparation method and application thereof. The glycyrrhetinic acid lutein ester compound provided by the invention is effective in inflammation relief, tissue repair and protection and treatment of ultraviolet injury, has good anti-inflammatory and antioxidant activity and repair capability, not only has good effects on anti-inflammatory, repair, anti-aging and blue light prevention of eyes, but also has good anti-inflammatory and anti-oxidation effects, and has good application prospects. Moreover, the composition has the effects equivalent to or even superior to those of special medicines in the aspects of skin state improvement, whitening, sunscreen, anti-aging and the like, and has good application prospects and potential.

The preparation method comprises the following steps: directionally enriching glycyrrhizic acid and liquiritin through a four-step process of temperature-controlled countercurrent extraction, acid precipitation and enrichment, membrane filtration and resin separation, and synchronously removing polysaccharides, pectin and bitter substance glycyrrhetinic acid residues. Compared with a traditional method, the method has the triple advantages that (1) the sweetness enhancing function is achieved, and glycyrrhizic acid and liquiritin cooperate to achieve 2-10 times of wine sweetness adjustment; 2) the stability is prominent, and the turbidity is only increased by 2NTU (25NTU in the traditional process) through 30-day acceleration test; 3) the sensory quality is optimized, and the sensory score of the blended wine body reaches 92 (the medicinal aroma and the wine aroma are harmonious and precipitate-free).

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The invention relates to the technical field of medicines, discloses an application of 18 beta-glycyrrhetinic acid in a TMAO inhibitor, and further discloses an application of 18 beta-glycyrrhetinic acid in preparation of medicines for treating chronic diseases such as chronic kidney disease (CKD) and the like. The invention provides 18 beta-glycyrrhetinic acid (18 beta-GA) which is a substance capable of effectively inhibiting choline in intestinal tracts from being metabolized into TMAO for the first time, and the 18 beta-GA is efficiently combined with CutC / D and FMO to inhibit the generation of TMAO, so that the aggravating effect of TMAO on chronic kidney diseases is relieved; the invention further provides a method for improving kidney diseases through a CXCL12 / CXCR4 signal axis after the TMAO is reduced by the 18 beta-glycyrrhetinic acid, a new thought and a new method are provided for developing medicines for treating the TMAO related diseases, and a new way is expected to be developed for treating the chronic kidney diseases.

The present application relates to the field of detection, and particularly relates to a hybridoma cell strain XXML-2G11A7, a preparation method and application thereof; the hybridoma cell strain XXML-2G11A7 has a preservation number of CGMCC NO: 46139, a preservation date of November 21, 2024, and a preservation unit of China General Microbiological Culture Collection Center, and a preservation unit address of No. 3, Institute of Microbiology, Chinese Academy of Sciences, 1st North Chenxi Road, Chaoyang District, Beijing; the antibody secreted by the hybridoma cell strain XXML-2G11A7 of the present application can specifically detect enoxolone, has high sensitivity and good accuracy.

The invention relates to a chemical control agent suitable for liquorice and screening of the chemical control agent. The chemical control agent is composed of uniconazole. The invention also provides application of uniconazole in preparation of the glycyrrhiza chemical control agent, and optionally, the chemical control agent has one or more of the following applications: a, reducing the area of glycyrrhiza leaves; b, increasing the chlorophyll content of licorice leaves; c, thickening the roots of the licorice roots; d, reducing the height of licorice plants; e, increasing underground biomass of liquorice; f, increasing the content of total flavonoids in liquorice roots; and g, increasing the content of one or more of glycyrrhizic acid, liquiritigenin, isoliquiritigenin and glycyrrhetinic acid of the licorice roots. The invention further provides a method for improving lodging resistance of liquorice. The method comprises the step of applying uniconazole to the liquorice. The invention provides a thought and a method for effectively controlling the plant height of liquorice and improving the economic benefit of liquorice cultivation, and lays a foundation for field management and sustainable development of subsequent liquorice cultivation.

The present invention provides a gel composition and an oil-in-water composition that have a strong barrier function.　The gel composition comprises: one or more first compounds, which are represented by polyoxyethylene phytosterols; one or more second compounds, which are represented by polyethylene glycol distearate; one or more third compounds, which are represented by polyoxyethylene alkyl ethers; and one or more fourth compounds selected from the group consisting of ascorbic acid and salts thereof, ascorbic acid monoesters, ascorbic acid diesters, tocopherols and esters thereof, glycyrrhetinic acid and esters and salts thereof, and betamethasone and esters thereof.

The invention discloses a preparation method and application of a hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid conjugate nanoparticle drug delivery system, and relates to the technical field of biological pharmacy. The key points of the technical scheme are as follows: GA and FA are respectively connected with HA by using adipic acid dihydrazide as a connexon; and the hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid polymer prodrugs are synthesized. An in-vitro release result shows that when the NPs are exposed in a physiological medium with slightly acidic pH, the drug release rate is higher than that in a blood environment with pH of 7.4. And the drug release rate and the drug release amount of the nanoparticles are superior to those of single drug release. The HA-ADH-GA and the HA-ADH-FANPs both have relatively low toxicity in vitro and a good effect of resisting the influenza A virus H1N1. Compared with the HA-ADH-FANPs, the HA-ADH-GANPs has the advantage that the HA-ADH-GANPs has a better protection effect on a mouse infected with the H1N1-UI182 in vivo.

The application discloses a lactobacillus crispatus based on multiple targets to realize anti-aging effect and application of transformation of glycyrrhiza for efficiency enhancement, and belongs to the technical field of microorganisms and the technical field of medicine. The lactobacillus crispatus CCFM1362 provided in the application can ferment glycyrrhiza extract, can improve the content of glycyrrhizic acid, hemiglycyrrhizin isoflavone B, naringenin chalcone and other substances, can enhance the efficacy of glycyrrhiza extract, and can realize the effect of multiple targets for anti-aging, and the specific embodiments are as follows: (1) the content of beta-galactosidase in liver tissue is inhibited; (2) the level of aging-related secretory phenotype in liver tissue is reduced; (3) the Nrf2 related pathway is activated, and the level of oxidative stress is reduced; (4) the NF-kappa B related pathway is activated, and the level of chronic inflammation is reduced. Therefore, the lactobacillus crispatus CCFM1362 and the glycyrrhiza extract have great application prospect in the production of anti-aging products.

The present invention relates to a self-assembled inclusion of glabridin with an ultra-small particle size, a preparation method, and an application thereof, and belongs to the field of cosmetic technology. The composition of the present invention comprises the following components in parts by weight: 0.5-5 parts of glabridin, 10-30 parts of polyol, 0.4-6.5 parts of a licorice carrier component, 1.5-3 parts of a nonionic emulsifier A, 0.45-1.8 parts of a nonionic emulsifier B, and 53.7-87.15 parts of water; the licorice carrier component comprises at least one of glycyrrhizic acid, ammonium glycyrrhizate, and glycyrrhetinic acid; the nonionic emulsifier A is a nonionic emulsifier with a hydrophilic-lipophilic balance value (HLB) greater than 9; the nonionic emulsifier B is a nonionic emulsifier with a hydrophilic-lipophilic balance value (HLB) of 2-4. The self-assembled inclusion of glabridin of the present invention has a smaller particle size, good encapsulation performance, and good targeting; it has good stability, the glabridin encapsulation does not precipitate, and the transdermal absorption rate is higher.

The invention relates to application of azole drugs in preparation of antifungal drugs, and belongs to the technical field of research and development of antifungal drugs. According to the application of the glycyrrhetinic acid combined with the azoles in preparation of the antifungal drugs, the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole shows a good synergistic effect or antagonistic effect on aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans, and the application of the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole in preparation of the antifungal drugs is disclosed. And a research and development direction is provided for preparing medicines for resisting aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans.

Provided are a cosurfactant-free microemulsion encapsulating glycyrrhetinic acid, a preparation method therefor, and use thereof. The cosurfactant-free microemulsion comprises carvacrol / thymol, a fatty acid, a nonionic surfactant, and water. Based on the mass percentage of the raw materials, the glycyrrhetinic acid accounts for 0.1-5%, the carvacrol / thymol accounts for 0.1-5%, the fatty acid accounts for 0.1-10%, the nonionic surfactant accounts for 1-30%, and the balance is made up to 100% with water. Carvacrol / thymol not only increases the solubility of glycyrrhetinic acid, but also promotes the transdermal absorption of glycyrrhetinic acid, and is a cosmetic composite efficacy composition having antioxidant, anti-inflammatory, and antibacterial effects.

The application discloses a kind of 18 beta-glycyrrhetinic acid ester derivatives with PPAR gamma agonistic activity and its preparation method and application, belongs to chemical pharmaceutical technical field, specifically related to a kind of 18 beta-glycyrrhetinic acid ester derivatives molecules and its application as PPAR gamma agonist in antitumor aspect.The application uses Steglich esterification reaction, with dicyclohexyl carbodiimide and 4-dimethylaminopyridine as catalyst, 18 beta-glycyrrhetinic acid is reacted with different types of carboxylic acid, and a kind of novel 18 beta-glycyrrhetinic acid ester derivative molecules are obtained by semi-synthesis;Computer simulation molecular docking and in vitro enzyme activity experiment show that this kind of molecule can be used as PPAR gamma agonist and play significant antitumor activity.

A composition for relieving hangovers and protecting the liver, made from the following raw materials in the indicated weight ratios: 3-20 parts of kudzu root extract, 2-20 parts of Japanese raisin tree fruit extract, 1-12 parts of N-acetylcysteine, 1-12 parts of L-ornithine, 1-15 parts of L-glutamine, 0.2-8 parts of glycyrrhetinic acid glycyrrhiza extract, 0.05-5 parts of curcumin, 0.005-0.5 parts of piperine, 0.5-10 parts of vitamin C, 0.01-2 parts of B vitamins complex, 0.1-8 parts of electrolyte salts, and 1-25 parts of honey or oligosaccharides.

The present invention belongs to the field of biomedicine and specifically discloses the use of glycyrrhetinic acid or glycyrrhetinic acid liposomes in the preparation of a drug for protecting against abdominal aortic aneurysms. It reveals that glycyrrhetinic acid can effectively ameliorate the mortality of mice following aortic rupture caused by Ang II treatment, significantly improve the degradation of the aortic elastic fiber layer caused by Ang II treatment, and promote the polarization of lipopolysaccharide (LPS)-induced macrophages toward the M2 type. Intervention with glycyrrhetinic acid before Ang II treatment can alleviate the occurrence of Ang II-induced abdominal aortic aneurysms and improve the survival rate of mice, indicating that glycyrrhetinic acid can be used to prepare a drug for alleviating abdominal aortic aneurysms. Furthermore, the present invention improves the solubility and bioavailability of glycyrrhetinic acid by encapsulating it in liposomes. At the same time, after glycyrrhetinic acid is encapsulated using nanotechnology, its dosage can be effectively controlled, further improving and enhancing the therapeutic effect of glycyrrhetinic acid.

The application provides a pharmaceutical composition for treating rheumatoid arthritis, which is composed of paeoniflorin, glycyrrhizin, glycyrrhizic acid and glycyrrhetic acid in a weight ratio of (4.5-7.5):(0.4-1.8):(1.8-4.3):(22-40). The pharmaceutical composition can significantly inhibit the proliferation of fibroblast-like synoviocytes, reduce the secretion of inflammation-related factors (TNF-alpha, IL-1beta, IL-6 and COX-2), regulate the expression of TNF-alpha / NF-kappaB signal pathway-related proteins, and has a significant curative effect on rheumatoid arthritis.

The main purpose set by the present inventors is to provide a technology for suppressing inflammation particularly in aged tissue in the oral cavity.　The present inventors have discovered that it is possible to suppress inflammation particularly in aged tissue in the oral cavity by an oral cavity composition that contains β-glycyrrhetinic acid and at least one selected from the group consisting of retinol acetate, retinol, all-trans-retinoic acid, ascorbic acid, cobalamin, calciferol, anthraquinone, L-histidine, methylhesperidin, and chemically possible salts thereof.

The invention discloses a method for preparing glycyrrhetinic acid under the assistance of mechanochemistry, which comprises the following specific operation processes: adding a pretreated liquorice raw material and a grinding aid into a ball milling tank of a ball mill, adding zirconium oxide beads to carry out co-grinding reaction, separating a product from the zirconium beads after the reaction is finished, and drying to obtain the glycyrrhetinic acid. And heating and hydrolyzing the product and an ethanol solution to obtain glycyrrhetinic acid. A mechanochemical one-step method is innovatively adopted, glycyrrhetinic acid can be efficiently prepared, the tedious steps of firstly extracting glycyrrhizic acid and then carrying out hydrolysis in a traditional process are thoroughly abandoned, glycyrrhetinic acid is prepared through mechanochemical assistance, and under the action of high-energy mechanical force, a grinding auxiliary agent and glycyrrhizic acid are promoted to be efficiently combined to promote glycyrrhizic acid hydrolysis; the preparation time is greatly shortened; and the generation of acid waste liquid is greatly reduced.

The invention belongs to the technical field of biology and new medicine, and discloses a preparation method of acoustic resonance driven glycyrrhizic acid nano-composite responsive gel, glycyrrhizic acid is used as a drug carrying system, berberine, ursolic acid, baicalein, luteolinin, curcumin, baicalin or ginsenoside Rh2 is used as a water-insoluble natural small molecule drug, and the acoustic resonance driven glycyrrhizic acid nano-composite responsive gel is prepared. Glycyrrhizic acid is an amphiphilic compound composed of one molecule of glycyrrhetinic acid and two molecules of glucuronic acid, a hydrophobic cavity can be formed in a water environment to wrap the water-insoluble natural small molecule medicine, a glycyrrhizic acid nano-composite solution is formed, and meanwhile the solubility of the water-insoluble natural small molecule medicine such as baicalein is improved.